Cancer is one of the most chronic and fatal disorders, involving abnormal cell growth with potential to spread or invade other parts of the body. Cancer is a life threatening disease, with extremely high mortality rate, due to highly invasive nature. Chemotherapy, abbreviated as, chemo or CTx is an important cancer treatment, in which cancer is treated by using combination of various anti-cancer agents (chemotherapeutic agents) as a part of standard chemotherapeutic regimen. Major drug classes of chemotherapeutic agents include anti-metabolites (purines, pyrimidines), alkylating agents (cisplatins, tetrazines), cytotoxic agents (anthracyclines), anti-microtubule agents (taxanes, vinca derivatives), and others. These drugs are highly effective in cancer treatment, but also cause chronic side effects. Chemotherapy induced pain is the most common side effect, which affects around 30% to 90% of cancer patients. If left untreated, it can affect the daily functions and quality of life as well as lead cancer patients to be less liable to continue their chemotherapy treatment.
Based on type of pain, the global chemotherapy induced pain market can be segmented into bone pain, nerve pain, muscle pain, abdominal pain, breakthrough cancer pain, peripheral neurotherapy, and others. Commonly used chemotherapy drugs such as Cisplatin, Vincristine Sulfate, and Paclitaxel cause chemotherapy induced peripheral neuropathy. In terms of therapy and treatment, the market can be categorized into medicinal treatment and non-medicinal treatment (supportive treatment). Medicinal treatment includes use of non-steroidal anti-inflammatory agents (NSAIDs) (aspirin, paracetamol, nimesulide, ibuprofen, and aceclofenac), opioid drugs (morphine), and others. Non-medicinal treatment includes massage, nutritional treatment, distraction, counseling and consultancy, exercise, and acupuncture. The global chemotherapy induced pain market is expected to experience sustained growth during the forecast period. This is attributed to various factors such as increase in research and development expenditure across the globe and high prevalence rate of cancer. According to the World Health Organization (WHO), cancer accounted for nearly 8.8 million deaths globally in 2015 and this number is projected to reach 13.1 million by 2030. This rapidly growing prevalence of cancer is likely to support the growth of chemotherapy practices which in turn is expected to boost the growth of the market. Owing to extensive R&D, a number of drugs and formulations are under clinical development and expected to enter the market during the forecast period. Moreover, rise in awareness among the population about chemotherapy related pain, increase in medical infrastructure, and technological advancements are projected to propel the market. However, promising pipeline molecules with disappointed results and rise in preference for other cancer treatment options are likely to hamper market growth.
Geographically, the global chemotherapy induced pain market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global chemotherapy induced pain market, followed by Europe, owing to strong clinical pipeline, developed health care infrastructure, and demand for advanced treatment options. Asia Pacific is an emerging market for chemotherapy induced pain treatment due to developing health care infrastructure and rise in government expenditure in the health care industry. Affordability issues, lack of proper treatment, and poor patient education are factors restraining the chemotherapy induced pain market in Middle East & Africa and Latin America.
Major players operating in the chemotherapy induced pain market include Amgen, Inc., Novartis International AG, GlaxoSmithKline plc, AstraZeneca plc, Pfizer, Inc., and Eli Lilly and Company.
This upcoming business intelligence report is intended to be a one-stop market research solution to guide organizations in taking timely and effective decisions for their business growth. The ongoing study is the culmination of our deep expertise on data science methods, combined with an unparalleled understanding of the external environment and analysis of the industries. Each of the reports by TMR aims at offering a detailed scrutiny of the value chain of our current and prospective customers, takes them from identifying value propositions, and subsequently assist their business executives to implement right strategies to create customer value. We believe that creating and sustaining the customer value is the key pivot on which business executives can create profits for their organizations and increase the market shares, continuously and with sustainability.
Each of our touchpoints through which we engage with the organization/enterprise during the primary research enables us to understand the internal environment it operates in and the ways in which the external environment influences its growth.
Always Evolving with Competition
Excellence is built into the DNA of TMR, and all our teams work collaboratively and committedly toward achieving that in whatever they do. From the very first interaction our teams of research analysts have with any interested market participant to the final preparation processes in each of our reports reflects a rigorous understanding of the dynamic industry environment that businesses operate in.
We relentlessly work to be a differentiator in whatever we do in the current era of hypercompetitive global environment. The result of our unceasing focus on excellence is reflected clearly in the insights and guidance we offer to our customers in order to empower them to create brand equity. Our simple yet very powerful underpinning for navigating the competition is to always keep evolving with changing business environments. Our close-kinit team of research analysts not only believe in this simple philosophy but also implement the same.
Constantly Innovating Our Research Methodologies and Models
We do not limit with any specific market research tool or one standard approach for obtaining or analyzing data. Undoubtedly, our report making process is ever-evolving to meet the customer needs and demands supported broadly by a vast knowledge of data science methods that we combine with business acumen our teams have built upon for several years. Evidently, our primary and secondary research data about customers and consumers have shown that we can go to any lengths to obtain them. This is followed by applying next-gen automation tools integrated with human judgement to clear the clutter, ascertain the most relevant and recent qualitative and quantitative insights, and package them in digestible chunks in our reports for our customers.
We Take Pride in No-One-Size-Fits-All Approach
Over the past several years, we have been conducting market intelligence studies across all industries for all types of organizations — big and small, profit and not-for-profit, and Fortune 500 and Unicorns, as we believe that a sound decision making must be based on no-one-size-fits-all approach. Without doubt, each of the organizations regardless of the industry they are in are affected differently by changes in political, economic, socio-culture, legal, ecological, and legal environments. The research models and the value chain analysis process that our analysts employ for conducting the study uphold this approach.
We look at myriad components of internal and external business environment affecting the growth strategies of organizations. Some of the broader aspects that we focus on are:
- Our team of Analysts and Support Teams always strive to see the bigger picture in life cycle stages of any industry
- The Teams focus on obtaining valuable insights into different models of competitive advantage while making an internal environment analysis
- They keep on modifying the value chain analysis processes of organizations to understand on how customer value is created
Some areas of assessing market dynamics that are used in the research models and methodologies adopted by our analysts can be summarized as:
- Corporate and business strategies underlying new brand positioning strategies
- Mapping for strategic planning for business units
- Various metrics for business portfolio analysis, including BCG matrix
- Value chain analysis
These will help create and sustain competitive advantage for our prospects and current customers.
Key focus areas and agenda that underpin and catalyze our primary and secondary research initiatives and endeavors are:
- What are some of the core competencies and distinctive competencies of new entrants and established players in the industry we are analyzing?
- What are some of the branding opportunities that are emerging at a rapid pace?
- What are the major competitive forces and elements of external environment shaping the industry life cycle stages of most organizations?
- Why some competitive strategies are popular than others among leaders in a certain market?
- What customer-based brand equity strategies companies have leveraged in a certain industry or set of related industries in a sector?
- What are some of the key pricing strategies that companies in an industry are implementing for marketing their products internationally?
- Identifying whether market-push or market-pull strategies are more relevant to a certain product or a service?
Disclaimer: This ongoing market research study is a meticulously planned activity where a broad array of factors and aspects that shape the marketing environment and industry are taken into account. However, keeping in mind the constantly changing nature of business dynamics and changing strategic intents, we are always actively making iterations and modifications in our approaches. As always, we are ready to tailor our insights and guidance to suit your requirements. Engage with us to know what more is there for your CXOs.